OTC · Healthcare
CV Sciences, Inc. (CVSI)
As-reported financials and recent SEC filings for CV Sciences, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$13.8M
Net income
$-958,000
Net margin
-6.9%
Diluted EPS
$-0.01
ROE
-65.3%
P/E (TTM)
—
Market cap
—
Debt / equity
0.3×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $13.8M | $15.7M | $16.0M | $16.2M | $20.0M |
| Gross profit | $6.8M | $7.2M | $7.1M | $5.5M | $8.6M |
| Operating income | $-470,000 | $-2.2M | $3.4M | $-6.8M | $-18.4M |
| Net income | $-958,000 | $-2.4M | $3.1M | $-8.2M | $-15.6M |
| Diluted EPS | $-0.01 | $-0.01 | $0.02 | $-0.07 | $-0.14 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-04
View on EDGAR →10-Q2026-05-15
View on EDGAR →8-K2026-05-14
View on EDGAR →DEF 14A2026-04-15
View on EDGAR →8-K2026-04-10
View on EDGAR →10-K2026-03-26
View on EDGAR →8-K2026-03-26
View on EDGAR →8-K2026-03-10
View on EDGAR →Largest Healthcare peers
Go deeper on CVSI
Search CV Sciences, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.